| Objective To analyze the pretreatment drug resistance and its influencing factors of HIV-1 infected people in a county of Liangshan Prefecture, so as to provide a theoretical basis for the formulation of specific antiretroviral therapy (ART) regimens and reduce the overall failure rate of ART. Methods?From June 2022 to December 2022, 107 HIV-1 infected patients who came to a county hospital in Liangshan Prefecture and planned to start ART were recruited. They underwent the gene detection of pretreatment drug resistance (PDR) and HIV-1 subtypes before treatment. At the same time, the baseline blood CD4+ T cell count, HIV-1 RNA and routine indicators were tested to analyze the overall incidence and related risk factors of PDR. Results?Among 107 HIV-1-infected persons, 101 cases were successfully amplified, with a success rate of 94.4%. Among 101 subjects, the main HIV-1 subtypes are B+C subtype recombination (48/101, 47.5%) and CRF07_ BC recombinant type (46/101, 45.5%). A total of 21 patients with drug resistance gene mutations were detected, with PDR accounting for 20.8%, and actual drug resistance 11 (drug resistance rate 10.9%). One case of NRTIs drug resistance mutation was A62V. There were 15 cases of NNRTIs drug resistance mutations, main mutations were K103N, Y181C, V179D and V179VD, which could cause different degrees of resistance to efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV) and etravirine (ETR) respectively. There were also 6 integrase inhibitor (INSTI) resistant mutations, including E157Q, A128T, G163R mutation sites. We found the Han nationality and virus type B+C were correlated with the occurrence of PDR mutations, in which the Han nationality was the risk factor and B+C was the protective factor. Conclusions?Among HIV-1 infected patients without receiving ART in a county of Liangshan Prefecture, a large proportion of PDR gene mutations were found. In addition to NRTIs and NNRTIs drug resistance, INSTI also appeared, which should be highly noticed. |